2025, Number 1
Clinical response to the use of an emollient plus (Atopeel body) in patients with mild-to-moderate atopic dermatitis
Full text
Language: Spanish
References: 14
Page: 8-14
PDF size: 198.48 Kb.
ABSTRACT
Importance: atopic dermatitis (AD) is a pathology with periods of relapse and remission, for which emollients are the main treatment. Emollients plus, such as Atopeel body, contain non-drug active substances, with moisturizing properties and anti-inflammatory effect, having the ability to repair the skin barrier.Objectives: to describe the clinical response to the use of an emollient plus (Atopeel body) in patients aged six months to 90 years with mild to moderate ad who were consulted in private dermatology practice between September and November 2022.
Methods: We conducted a retrospective observational cohort study of five private practice dermatologists in Colombia. We included patients between six months and 90 years of age with a confirmed clinical diagnosis of mild to moderate AD. Clinical response was evaluated with the SCORAD, EASI and DLQI scales.
Results: We included 93 patients with mild to moderate AD. At baseline, 60.2% of patients had moderate ad by scorad. Clinical response to Atopeel body was associated with a decrease in the scale at 22.6, 3.2 and 1.1% (p ‹ 0.001) during each follow-up. We also observed a decrease in topical corticosteroid consumption (p ‹ 0.001).
Conclusions: it appears that consistent and daily use of Atopeel body as an adjuvant therapy in patients with mild to moderate AD reduces the likelihood of relapses and the use of topical steroids and its side effects.
REFERENCES
Furue M, Chiba T, Tsuji G, Ulzii D, Kido-Nakahara M, Nakahara T yKadono T, Atopic dermatitis: immune deviation, barrier dysfunction,ige autoreactivity and new therapies, Allergology International:official journal of the Japanese Society of Allergology2017; 66(3):398-403. Disponible en: https://doi.org/10.1016/j.alit.2016.12.002.
Toledo MF, Saraiva-Romanholo BM, Oliveira RC, Saldiva PHN,Silva LFF, Nascimento LFC et al., Changes over time in theprevalence of asthma, rhinitis and atopic eczema in adolescentsfrom Taubaté, São Paulo, Brazil (2005-2012): relationship withliving near a heavily travelled highway, Allergol Immunopathol(Madrid) 2016; 44(5):439-44.
Wollenberg A, Kinberger M, Arents B, Aszodi N, Ávila Valle G,Barbarot S, Bieber T, Brough HA, Calzavara Pinton P, Christen-Zäch S, Deleuran M, Dittmann M, Dressler C, Fink-Wagner AH,Fosse N, Gáspár K, Gerbens L, Gieler U, Girolomoni G, GregoriouS, Mortz CG, Nast A, Nygaard U, Redding M, RehbinderEM, Ring J, Rossi M, Serra-Baldrich E, Simon D, Szalai ZZ, SzepietowskiJC, Torrelo A, Werfel T y Flohr, European guideline(EuroGuiDerm) on atopic eczema: part i: systemic therapy, JEur Acad Dermatol Venereol 2022; 36:1409-31. Disponible en:https://doi.org/10.1111/jdv.18345.
Wollenberg A, Barbarot S, Bieber T, Christen-Zaech S, DeleuranM, Fink-Wagner A, Gieler U, Girolomoni G, Lau S, Muraro A,Czarnecka-Operacz M, Schäfer T, Schmid-Grendelmeier P, SimonD, Szalai Z, Szepietowski JC, Taïeb A, Torrelo A, Werfel T,Ring J, European Dermatology Forum (edf), European Academyof Dermatology and Venereology (eadv), European Academy ofAllergy and Clinical Immunology (eaaci), European Task Forceon Atopic Dermatitis (etfad), European Federation of Allergyand Airways Diseases Patients’ Associations (efa), EuropeanSociety for Dermatology and Psychiatry (esdap), European Societyof Pediatric Dermatology (espd), Global Allergy and AsthmaEuropean Network (ga2len) y European Union of Medical Specialists(uems), Consensus-based European guidelines for treatmentof atopic eczema (atopic dermatitis) in adults and children:part i, J Eur Acad Dermatol Venereol 2018; 32(5):657-82. doi:10.1111/jdv.14891. Fe de erratas en: J Eur Acad Dermatol Venereol2019; 33(7):1436. pmid: 29676534.